NCT06742125 (DCB-STEMI) is a NA clinical trial of Drug-coated balloon (DCB) in ST-elevation Myocardial Infarction (STEMI), sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT06742125?

NCT06742125 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT06742125?

Interventions in NCT06742125: Drug-coated balloon (DCB), Drug-eluting stent (DES).

What condition does NCT06742125 study?

NCT06742125 studies ST-elevation Myocardial Infarction (STEMI).

Is NCT06742125 still recruiting?

NCT06742125 is currently recruiting now. Last updated 29 January 2026.

Last reviewed 2026-01-29 · How we verify

NCT06742125: DCB-STEMI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug-Coated Balloon Versus Drug-Eluting Stent in Patient With ST-Segment Elevation Myocardial Infarction

Recruiting now NA Last updated 29 January 2026

What this trial tests

NA trial testing Drug-coated balloon (DCB) in ST-elevation Myocardial Infarction (STEMI) in 1,244 participants. Currently enrolling.

Timeline

31 May 2025

Primary endpoint
1 January 2032

1 January 2032

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,244
Start date	31 May 2025
Primary completion	1 January 2032
Estimated completion	1 January 2032
Sites	1 location across China

Drugs / interventions tested

Drug-coated balloon (DCB)
Drug-eluting stent (DES)

Conditions studied

ST-elevation Myocardial Infarction (STEMI) — all drugs for ST-elevation Myocardial Infarction (STEMI) →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

18 and older, any sex, with ST-elevation Myocardial Infarction (STEMI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute ST-segment elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate intervention. The incidence of premature coronary artery disease (PCAD) is rising rapidly in China; its long-term prognosis remains poor and it frequently progresses to acute myocardial infarction, necessitating high-risk therapies such as primary percutaneous coronary intervention (PCI) or coronary artery bypass grafting, thereby imposing enormous economic and psychological burdens on patients and their families. Moreover, the cumulative 6-year rate of death or myocardial infarction after implantation of the latest-generation drug-eluting stents still reaches 15%, and management of stent failure is extremely challenging. Drug-coated balloon (DCB) angioplasty-representing the "leave-nothing-behind" paradigm-is a highly promising option in young subjects. Accumulating clinical evidence demonstrates that DCB provides favorable efficacy across a broad spectrum of lesions, including small-vessel and large-vessel de novo disease, bifurcation lesions, and in-stent restenosis. Nevertheless, high-quality data on the impact of DCB angioplasty in de novo large-vessel disease and in the setting of acute STEMI are still lacking.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for ST-elevation Myocardial Infarction (STEMI)

Currently open trials in the same condition.

NCT07361783 — Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial · NA · recruiting
NCT06965023 — Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI) · recruiting
NCT04825743 — A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI · Phase 3 · active not recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06742125 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 29 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06742125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing